Maria Walls
Adult Health · Saint Louis, MONPI 1740517515
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,107 of the $68,809 with a category attached, or 83.0%. Novo Nordisk accounts for 95.3% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $31,205, more than ten times the $870 reported in 2021. Among adult health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $342.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$66K
- Lilly USA, LLC$523
- AbbVie$345
- AstraZeneca$315
- Edwards Lifesciences$243
- GSK$193
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$57,10783%
- Travel & lodging$4,4957%
- Food & beverage$6,94210%
- Education$2650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 115 | $65,592 |
| Lilly USA, LLC | 14 | $523 |
| AbbVie | 15 | $345 |
| AstraZeneca | 6 | $315 |
| Edwards Lifesciences | 3 | $243 |
| GSK | 5 | $193 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $122 |
| Kyowa Kirin, Inc. | 1 | $122 |
| Inspire Medical Systems, Inc. | 1 | $121 |
| Avanir Pharmaceuticals, Inc. | 1 | $120 |
| Rhythm Pharmaceuticals, Inc. | 1 | $108 |
| Genentech USA, Inc. | 1 | $106 |
| Pfizer | 6 | $102 |
| Tactile Systems Technology Inc | 1 | $101 |
| Biohaven Pharmaceuticals, Inc. | 2 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Abbott | 3 | $47 |
| Bayer | 2 | $47 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Lundbeck LLC | 1 | $39 |
| Merck | 2 | $35 |
| Exact Sciences | 2 | $33 |
| Corcept Therapeutics | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$55,261
- Saxenda$5,401
- ZEPBOUND$227
- INGREZZA$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$123
- SHINGRIX$123
- IBSRELA$122
- NOURIANZ$122
- FARXIGA$121
- Inspire$121
- NUEDEXTA$120
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$119
- FASENRA$110
- Imcivree$108
- Xofluza$106
- Flexitouch Plus$101
- Entre Plus$101
How this compares
$68,809 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 78 | $84,690 |
| OzempicSemaglutide | 67 | $77,999 |
| EliquisApixaban | 19 | $27,280 |
| JardianceEmpagliflozin | 33 | $26,505 |
| XareltoRivaroxaban | 23 | $22,225 |
| FarxigaDapagliflozin Propanediol | 14 | $14,058 |
| MyrbetriqMirabegron | 13 | $13,679 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 19 | $5,280 |
| Vilazodone Hcl | 16 | $3,501 |
| SynthroidLevothyroxine Sodium | 27 | $2,183 |
| Bupropion XlBupropion Hcl | 60 | $1,759 |
| Duloxetine Hcl | 72 | $1,592 |
| Levothyroxine Sodium | 131 | $1,516 |
| Gabapentin | 69 | $1,310 |
| Omeprazole | 81 | $1,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $523 | $84,69078 claims |
| Novo NordiskOzempic | $65,592 | $77,99967 claims |
| PfizerEliquis | $102 | $27,28019 claims |
| Boehringer IngelheimJardiance | $13 | $26,50533 claims |
| Johnson & JohnsonXarelto | $15 | $22,22523 claims |
| AstraZenecaFarxiga | $315 | $14,05814 claims |
| GSKArexvy | $193 | $5,28019 claims |
| AbbVieSynthroid | $345 | $2,18327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.
Other adult health in Saint Louis
- Stephanie VogelSaint Louis$115K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Jennifer SpeiserSaint Louis$27K
- Michele NobsSaint Louis$15K
- Lisa Koester WiedemannSaint Louis$14K
- Erin DoserSaint Louis$13K
- Marcee StegemeierSaint Louis$12K
- Heather PophamSaint Louis$10K
- Denise ApprillSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.